Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29855979 | 0.98 | FFAR2 (0.72) | FFAR2LMNAUSP2TSHRSCN3A | |
| SCHEMBL13694245 | 0.85 | MAPK8 (0.63) | FFAR2LMNAUSP2TSHRRAB9A | |
| SCHEMBL1458948 | 0.85 | PKM (0.67) | LMNAUSP2TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL27874867 | 0.85 | RAB9A (0.62) | FFAR2LMNAUSP2TSHRSCN3A | |
| SCHEMBL31207176 | 0.84 | FFAR2 (0.64) | FFAR2LMNAUSP2TSHRSCN3A | |
| SCHEMBL23657933 | 0.83 | PRKACA (0.61) | FFAR2LMNAUSP2TSHRRAB9A | |
| SCHEMBL11627595 | 0.83 | ROCK1 (0.61) | FFAR2LMNAUSP2TSHRSCN3A | |
| SCHEMBL1358311 | 0.82 | KDM4E (0.67) | FFAR2LMNAUSP2TSHRRAB9A | |
| SCHEMBL18956343 | 0.82 | ALDH1A1 (0.70) | LMNAUSP2TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL29911992 | 0.82 | ALDH1A1 (0.65) | FFAR2LMNAUSP2TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160311-B | Difunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-115109055-B | Difunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-115160311-A | Bifunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-115109055-A | Bifunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-100506807-C | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-07-01 | — | — | CN | claimed |
| CN-101434585-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | claimed |
| CN-1286835-C | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2006-11-29 | — | — | CN | claimed |
| EP-1724270-A2 | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | Pfizer Italia S.r.l. (IT) | 2006-11-22 | — | — | EP | claimed |
| EP-1406899-B1 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2006-11-15 | — | — | EP | claimed |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | claimed |
| CN-1531535-A | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | — | 2004-09-22 | — | — | CN | claimed |
| EP-1406899-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | claimed |
| WO-2003008365-A2 | PHENYLACETAMIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2003-01-30 | — | — | WO | claimed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | claimed |
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250388573-A1 | FUSED BICYCLIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0772606-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003392-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB3, ERBB2 | FFAR2 564/4885LMNA 4706/4885USP2 2262/4885 |
| US-20250388573-A1 | FUSED BICYCLIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | FFAR2 660/4885LMNA 4146/4885USP2 3259/4885 |
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | CDK2, CDK1, CDKN1A | FFAR2 4127/4885LMNA 3198/4885USP2 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.